Gsk (GSK) Cost of Revenue (2009 - 2026)

Gsk's Cost of Revenue history runs 18 years deep, the most recent figure standing at $3.0 billion for Q2 2026.

• In Q2 2026, Cost of Revenue rose 5.26% year-over-year to $3.0 billion; the TTM figure through Jun 2026 stood at $20.6 billion (up 2.76% YoY), while the FY2025 annual figure was $11.9 billion, up 2.79% from the prior year.
• Cost of Revenue for Q2 2026 stood at $3.0 billion, up from $2.5 billion in the prior quarter.
• The five-year high for Cost of Revenue was $12.0 billion in Q4 2025, with the low at $2.4 billion in Q1 2023.
• The 5-year median for Cost of Revenue is $2.9 billion (2025), against an average of $4.7 billion.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue jumped 147.27% in 2022, then plunged 35.22% in 2023.
• Gsk's Cost of Revenue stood at $11.2 billion in 2022, then slipped by 5.14% to $10.6 billion in 2023, then increased by 9.24% to $11.6 billion in 2024, then grew by 3.28% to $12.0 billion in 2025, then tumbled by 74.65% to $3.0 billion in 2026.
• Business Quant data shows GSK's Cost of Revenue at $3.0 billion in Q2 2026, $2.5 billion in Q1 2026, and $12.0 billion in Q4 2025.